These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1317828)

  • 1. Fluoxetine treatment of the obese diabetic.
    Gray DS; Fujioka K; Devine W; Bray GA
    Int J Obes Relat Metab Disord; 1992 Mar; 16(3):193-8. PubMed ID: 1317828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized double-blind clinical trial of fluoxetine in obese diabetics.
    Gray DS; Fujioka K; Devine W; Bray GA
    Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 4():S67-72. PubMed ID: 1338389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study.
    Daubresse JC; Kolanowski J; Krzentowski G; Kutnowski M; Scheen A; Van Gaal L
    Obes Res; 1996 Jul; 4(4):391-6. PubMed ID: 8822764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of fluoxetine in obese elderly patients with type 2 diabetes.
    Connolly VM; Gallagher A; Kesson CM
    Diabet Med; 1995 May; 12(5):416-8. PubMed ID: 7648804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss.
    Maheux P; Ducros F; Bourque J; Garon J; Chiasson JL
    Int J Obes Relat Metab Disord; 1997 Feb; 21(2):97-102. PubMed ID: 9043962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
    Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoxetine therapy in obese diabetic and glucose intolerant patients.
    Kutnowski M; Daubresse JC; Friedman H; Kolanowski J; Krzentowski G; Scheen A; Van Gaal L
    Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 4():S63-6. PubMed ID: 1338388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Toplak H; Hamann A; Moore R; Masson E; Gorska M; Vercruysse F; Sun X; Fitchet M
    Int J Obes (Lond); 2007 Jan; 31(1):138-46. PubMed ID: 16703004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals.
    Potter van Loon BJ; Radder JK; Frölich M; Krans HM; Zwinderman AH; Meinders AE
    Int J Obes Relat Metab Disord; 1992 Feb; 16(2):79-85. PubMed ID: 1316330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoxetine: a randomized clinical trial in the maintenance of weight loss.
    Goldstein DJ; Rampey AH; Dornseif BE; Levine LR; Potvin JH; Fludzinski LA
    Obes Res; 1993 Mar; 1(2):92-8. PubMed ID: 16350565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoxetine in the treatment of obese type 2 diabetic patients.
    O'Kane M; Wiles PG; Wales JK
    Diabet Med; 1994; 11(1):105-10. PubMed ID: 8181239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity.
    Breum L; Bjerre U; Bak JF; Jacobsen S; Astrup A
    Metabolism; 1995 Dec; 44(12):1570-6. PubMed ID: 8786726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients.
    Potter van Loon BJ; Radder JK; Frölich M; Krans HM; Zwinderman AH; Meinders AE
    Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 4():S55-61. PubMed ID: 1338387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.
    Berne C;
    Diabet Med; 2005 May; 22(5):612-8. PubMed ID: 15842517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
    Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
    Garvey WT; Birkenfeld AL; Dicker D; Mingrone G; Pedersen SD; Satylganova A; Skovgaard D; Sugimoto D; Jensen C; Mosenzon O
    Diabetes Care; 2020 May; 43(5):1085-1093. PubMed ID: 32139381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study).
    Hollander P; Lasko B; Barnett AH; Bengus M; Kanitra L; Pi-Sunyer FX; Balena R
    Obesity (Silver Spring); 2013 Feb; 21(2):238-47. PubMed ID: 23404788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoxetine increases resting energy expenditure and basal body temperature in humans.
    Bross R; Hoffer LJ
    Am J Clin Nutr; 1995 May; 61(5):1020-5. PubMed ID: 7733022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.